Safety and Efficacy Study of TQ-B3101 in Patients With ROS1-positive Non-Small Cell Lung Cancer (NSCLC)
Status:
Unknown status
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
To assess efficacy and safety of oral TQ-B3101 administered to patients with Advanced
Non-Small Cell Lung Cancer (NSCLC) that confirmed ROS1 positive gene mutation.